Reniochalistatin E: A potentiating agent and a potential novel drug delivery platform
Bioorganic Chemistry · 2025
DOI: 10.1016/j.bioorg.2025.108331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Kameron R Wildeman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Kansas State University, Manhattan, KS 66506, United States of America. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Screening Assays, Antitumor. Die Arbeit nennt 32 Literaturangaben. Gefördert von: National Science Foundation, National Institutes of Health, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Kansas State University, Manhattan, KS 66506, United States of America.
- Department of Chemistry, Kansas State University, Manhattan, KS 66506, United States of America. Electronic address: rjraff@ksu.edu.
Förderung
- National Science Foundation
- National Institutes of Health
- National Institute of General Medical Sciences
- Kansas State University
- Johnson Cancer Research Center, Kansas State University
Zitieren
APA
Wildeman, K. R., Barnett, M., Fatino, A., Weeramange, C., & Rafferty, R. J. (2025). Reniochalistatin E: A potentiating agent and a potential novel drug delivery platform. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.108331
Vancouver
Wildeman KR, Barnett M, Fatino A, Weeramange C, Rafferty RJ. Reniochalistatin E: A potentiating agent and a potential novel drug delivery platform. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.108331
BibTeX
@article{Wildeman2025,
author = {Wildeman, Kameron R and Barnett, Matthew and Fatino, Anthony and Weeramange, Chamitha and Rafferty, Ryan J},
title = {Reniochalistatin E: A potentiating agent and a potential novel drug delivery platform},
journal = {Bioorganic Chemistry},
year = {2025},
doi = {10.1016/j.bioorg.2025.108331}
}
EUVIMED